---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008118"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:16:48.413075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure reports Q1 net loss $16.1M, cash $145.5M; pipeline data expected Q4 2023

## Summary
- Net loss $16.1M for Q1 2023 vs $20.6M loss in Q1 2022, narrowing on lower R&D expenses.
- Cash $145.5M down from $159.9M; expects runway into mid-2025.
- Three clinical programs (NC410, NC762, NC525) data updates expected in Q4 2023.
- First patient dosed with NC525 (LAIR-1 mAb) Phase 1 in AML in Feb 2023.
- R&D expenses decreased to $11.6M from $15.0M YoY.

## SEC filing metadata
- accession: 0001558370-23-008118
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/0001558370-23-008118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/nxtc-20230504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008118
- JSON: https://secwatch.observer/filing/0001558370-23-008118.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008118.txt

## Key facts
- Earnings Releases
  NextCure, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported first quarter 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/0001558370-23-008118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.